�鶹Ů��

Schools across the country keep EpiPens in their nurses’ offices in case a student has a severe allergic reaction. For years, Mylan Pharmaceuticals has been selling the devices to schools at a discounted price, giving them a break from rising costs. But the program also prohibited schools from buying competitors’ devices — a provision that experts say may have violated antitrust law. (Swetlitz and Silverman, 8/25)

Like other lawmakers now calling for an investigation of the massive hikes in the price of EpiPens, Sen. Richard Blumenthal backed legislation that encouraged schools to stock the auto-injector that delivers a drug that counters the effects of a potentially fatal allergic reaction. In 2013, Blumenthal was an original co-sponsor of a bill – which became law – that awards grants to states that require their public elementary and secondary schools to maintain a supply of emergency epinephrine, the drug delivered by EpiPens. (Radelat and Constable, 8/24)

File this under “Another day, another lawmaker is leaning on Mylan Laboratories.” The US senators who head the Special Committee on Aging are the latest politicians to demand the company explain the pricing behind its EpiPen injector for allergic reactions. And not only does the committee want Mylan to provide information reviewed by its board of directors, the committee also asked the drug maker to schedule a face-to-face briefing over the next two weeks. (Silverman, 8/24)